{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pegu A"],"funding":["Intramural NIH HHS","Woodruff Health Sciences Center","NCATS NIH HHS","Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children’s Healthcare of Atlanta","Vaccine Research Center","Emory Executive Vice President for Health Affairs Synergy Fund Award","NIAID NIH HHS","National Institutes of Health","Coalition for Epidemic Preparedness Innovations","Intramural Research Program of the Vaccine Research Center, NIAID, NIH","NIH HHS"],"pagination":["1372-1377"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8691522"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["373(6561)"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of "],"journal":["Science (New York, N.Y.)"],"pubmed_title":["Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants."],"pmcid":["PMC8691522"],"funding_grant_id":["UM1 AI148373","HHSN272201500002C","P51 OD011132","UM1 AI148684","UM1 AI148576","TMPRSS2","UL1 TR001863","Z99 AI999999","2020 COVID-19 CURE AWARD","U01 AI151698","UM1AI148373","R21 AI158788","UM1AI148576, UM1AI148684, P51OD011132"],"pubmed_authors":["Hoang B","Gibson T","Arega J","Boritz EA","Gordon I","Pruijssers AJ","O'Connell SE","Shi W","Bechnak A","Hughes T","Nason MC","Martinez DR","Costner P","Benoit J","Witte M","Carlton K","Louder MK","Russell J","Scherer E","Carste B","Widge AT","Ackerley CMG","Phadke VK","Munt J","Denison MR","Baric RS","McDermott AB","Drobeniuc A","Ledgerwood JE","Roberts PC","Corbett KS","Lee S","Novik L","Roederer M","Douek DC","Erolin R","Chappell JD","Mallory M","Doria-Rose NA","Macenczak H","Suthar MS","Menachery V","Neuzil KM","Berkowitz NM","Edwards C","mRNA-1273 Study Group§","Swanson PA","Beigel JH","Leav B","Posavad CM","Nayak S","Schmidt SD","Suyehira J","Pegu A","Barr L","Kelley C","Sherman A","McCullough MP","Makowski M","Rouphael NG","Mascola JR","Luke C","Larsen SE","Buchanan W","Zaks T","Jackson LA","Stevens LJ","Yang ES","Elsafy M","Stephens K","Lu X","Peters E","Koo H","Wang L","Rouphael N","Edara VV","Creanga A","Shi PY","Kolhekar A","Camacho-Gonzalez AF","Pikaart-Tautges R","Holman L","Traenkner J","O'Connell S","Floyd K","Sun W","Lampley R","Yildirim I","Winston J","Hurley M","Lasicka S","Talana CA","Lindesmith LC","Makhene M","Bower M","Flach B","Choe J","Fields C","Pajon R","Dunstan M","Rostad CA","Padilla M","Edupuganti S","Pimienta S","Ffitch J","Gale M","Kamidani S","Kao C","Anderson EJ","Kunwar P","O'Dell S","Rebolledo PA","Johnson B","Jackson L","Teherani M","Carfi A","Bennett H","Graham BS","Nguyen M","Luke CJ","Altaras NE","Zhang Y","Albert J","Gaudinski M","Leung K","Anderson E","Lin BC","Lai L","Collins M","Sindall E","Kiniry E","Morabito KM","Coler RN"],"additional_accession":[]},"is_claimable":false,"name":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.","description":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-04T10:27:15.755Z","creation":"2025-04-04T10:27:15.755Z"},"accession":"S-EPMC8691522","cross_references":{"pubmed":["34385356"],"doi":["10.1126/science.abj4176"]}}